This week PNAS published follow-up study from Harvey Cantor's lab examining role of Helios (the Sun in Greek mythology) in Foxp3+ TREG stability. In this new study they showed that antibody [anti-GITR]-mediated down-regulation of Helios in Foxp3+ TREG causes them to acquire effector function and participate in anti-tumor response.
I will highlight relevant findings. The first finding was that mice with Helios-deficient Foxp3+ TREG showed additional resistance to tumor (however, please note that tumor growth pattern and mice survival do not correlate in Heliosfl/fl.FoxP3-Cre mice).
Similar tumor growth retardation was observed in adoptive co-transfer experiment with WT T cells and Helios-KO Foxp3+ TREG.
Mechanistically, Heliosfl/fl.FoxP3-cre TREG up-regulated effector cytokines specifically at tumor site.
Finally, treatment of mice with antibody, DTA-1, directed to GITR (glucocorticoid induced TNF receptor), caused Helios down-regulation in FoxP3+ TREG and improved tumor protection.
In summary, the authors proposed that therapeutic targeting of Helios expression in tumor-associated FoxP3+ TREG could convert them from tolerogenic cells into anti-cancer fighting cells (however, please note the authors did not formally test whether anti-cancer effect of anti-GITR antibody was indeed mediated via its effect on Helios in FoxP3+ TREG).
David Usharauli
I will highlight relevant findings. The first finding was that mice with Helios-deficient Foxp3+ TREG showed additional resistance to tumor (however, please note that tumor growth pattern and mice survival do not correlate in Heliosfl/fl.FoxP3-Cre mice).
Similar tumor growth retardation was observed in adoptive co-transfer experiment with WT T cells and Helios-KO Foxp3+ TREG.
Mechanistically, Heliosfl/fl.FoxP3-cre TREG up-regulated effector cytokines specifically at tumor site.
Finally, treatment of mice with antibody, DTA-1, directed to GITR (glucocorticoid induced TNF receptor), caused Helios down-regulation in FoxP3+ TREG and improved tumor protection.
In summary, the authors proposed that therapeutic targeting of Helios expression in tumor-associated FoxP3+ TREG could convert them from tolerogenic cells into anti-cancer fighting cells (however, please note the authors did not formally test whether anti-cancer effect of anti-GITR antibody was indeed mediated via its effect on Helios in FoxP3+ TREG).
David Usharauli
No comments:
Post a Comment